Ankit Mahadevia, CEO and President at Spero Therapeutics, Inc. (SPRO), sold 28,839 shares at $14.28 ($412K) on 2020-10-13, disclosed to the SEC on 2020-10-15.
Open-market sale of $412k SPRO by CEO and President. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.28 | 14,367 | $205K | 49.8% |
| 2 | $14.28 | 14,367 | $205K | 49.8% |
| 3 | $14.25 | 105 | $1K | 0.4% |
| Total | $14.28 avg | 28,839 | $412K | 100% |
| Filing → |
| SPRO | SELL | 2024-08-29 | $8K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |